Glaucoma Surgery Market Scenario:
Glaucoma refers to a condition which causes blindness. It is a chronic and permanent disorder whose prevalence’s is increasing with increasing age. Beside this different diseases like diabetes and deficiency of vitamins can also cause this disease. The major driving factor for the growth of this market is increasing aging population across the globe and increasing the prevalence of diabetes. Changing lifestyle and unhealthy food has given a push for the growth of Glaucoma Surgery Market. On the other hand, preference of minimum surgery and the high cost of the surgical treatment can hamper the growth of the market.
Glaucoma Surgery Market Segmentation:
Glaucoma surgery market is classified as target as trabecular meshwork, suprachoroidal space and others.
According to surgery, the market is categorized as angle closure glaucoma surgery, laser surgery, aqueous shunt surgery, and other.
On basis of end user market segmentation includes hospital, ambulatory surgery centers and other.
Glaucoma Surgery Market Regional Analysis:
Geographic segmentation of glaucoma surgery market includes North America, Europe, Asia Pacific and Middle East and Africa regions.
With the expanding geriatric population and advancement in surgery technologies, North America glaucoma surgery market has been growing exponentially. Increasing expenditure on healthcare and improved infrastructure will impact the growth of the market. Europe has the second largest share in the glaucoma surgery market followed by Asia Pacific. A vast population of the region, especially that of the older generation as well as rapid development in healthcare sector has added impetus to the market.
Glaucoma Surgery Market Players:
Some of the players in the glaucoma surgery market include Novartis AG, Allergan, Merck & Co., Inc., Abbott, Akorn, Inc., Teva Pharmaceuticals, Bausch & Lomb, Pfizer, Santen, Carl Zeiss Meditec, Alcon, Ellex Medical Lasers, Lumenis, Topcon Medical Systems, Nidek, OPHTEC, Optos, Accutome, AqueSys, Canon, Essilor, Iridex Corporation etc.
Browse Full Report with TOC at: https://www.marketresearchfuture.com/reports/glaucoma-surgery-market-1342
Glaucoma Surgery Industry News:
Recently BioMed, a commercial stage biotech company, announced that Mannin, the technology partner of BioMed, has won a UDS 7.5 million grant from the German state of Saxony. Mannin is a research-stage biotech company that aims on discovering, developing and commercializing therapeutics designed for vascular diseases. The grant is for funding of development of innovative treatments for glaucoma. With the grant, Q BioMed and Mannin can significantly accelerate research and development of therapeutic solutions.
In another recent move, ELT Sight, Inc. a company that focuses on long term microinvasive glaucoma surgery, announced that it has acquired the IP and assets of MLase AG excimer ophthalmic laser system. MLase is the manufacturer and marketer of novel laser systems, that include ExTra ELT Laser and disposable applicator used to perform implant-free, microinvasive glaucoma surgery.